What exactly is capromorelin and how does it get a dog to eat again?

Capromorelin is a synthetic ghrelin receptor agonist, meaning it binds to the same receptors in the brain and stomach that the natural hormone ghrelin activates to trigger hunger. The U.S. Food and Drug Administration approved the drug under the brand name Entyce in May 2016 as the first medication cleared specifically for appetite stimulation in dogs, and later approved a related formulation, Elura, for cats in 2021 (U.S. Food and Drug Administration, 2021). Unlike older appetite stimulants such as mirtazapine, which were borrowed from human medicine and used off-label, capromorelin went through formal veterinary clinical trials for this exact purpose.

The drug is dispensed as a flavored oral liquid measured in milliliters per pound of body weight, and most dogs take it directly from the syringe or mixed into a small amount of food. Because it acts on the ghrelin pathway rather than simply masking nausea, veterinarians often describe its effect as making a dog genuinely hungry again rather than just tolerating food that's put in front of it (Merck Veterinary Manual, 2022).

When would a vet actually prescribe this instead of just waiting it out?

Veterinarians reach for capromorelin when a dog's poor appetite is a symptom rather than the whole problem — for example, during chronic kidney disease, chemotherapy, chronic gastrointestinal disease, or recovery from major surgery where inadequate calorie intake can slow healing and worsen muscle wasting. The American Animal Hospital Association's cancer management guidelines note that maintaining lean body mass through nutritional support is a core part of supportive oncology care, since unintended weight loss is linked to worse outcomes in dogs undergoing treatment (American Animal Hospital Association, 2016).

It's also commonly used short-term after anesthesia or illness when a dog simply won't eat enough to meet its calorie needs, buying time for the underlying condition to improve or for a longer-term feeding plan to take effect. It is not intended as a substitute for diagnosing why the appetite loss started; a vet will typically run bloodwork or imaging first to rule out treatable causes before adding an appetite stimulant to the plan.

How is it dosed, and how fast will I see my dog eating more?

Entyce is labeled for once-daily oral dosing, typically around 3 mg per kilogram of body weight, given at least an hour before or after a meal for best absorption, according to the product's FDA-approved labeling (U.S. Food and Drug Administration, 2016). Many owners and veterinarians report a noticeable pickup in interest in food within 24 to 48 hours, though the exact timeline can vary with the underlying disease being treated.

Dosing is calculated from the dog's current weight, so weigh-ins matter, especially in dogs that are actively losing weight during treatment — a dose that was correct two weeks ago may need adjusting. The liquid should be measured with the syringe provided rather than a household spoon, since even small dosing errors add up over a course of daily treatment.

What side effects should I watch for after starting this medication?

The most frequently reported side effects in the clinical studies submitted to the FDA were vomiting, diarrhea, excessive salivation, and polydipsia (increased thirst), most of which were mild and resolved without stopping the drug (U.S. Food and Drug Administration, 2016). Some dogs also show mild, transient elevations in blood pressure or heart rate, which is why vets may recheck vitals in dogs with pre-existing cardiac disease.

Because capromorelin also has a mild effect on growth hormone and insulin-like growth factor 1 (IGF-1) release, it isn't recommended for use in breeding animals or in dogs with uncontrolled endocrine disorders such as unregulated diabetes, per the product labeling. Owners should report any repeated vomiting, lethargy, or refusal to even attempt eating despite the medication to their veterinarian rather than assuming the drug simply isn't working.

Are there dogs or cats that shouldn't take capromorelin?

The label advises caution in animals with hepatic (liver) impairment, since the drug is metabolized in the liver, and in patients with known hypersensitivity to capromorelin or any inactive ingredients in the formulation (U.S. Food and Drug Administration, 2016). It has not been evaluated for safety in dogs younger than roughly 4 months of age or in pregnant or lactating animals, so vets generally avoid it in those groups.

Because ghrelin receptor agonists can influence blood glucose and growth hormone pathways, veterinarians typically weigh the risks and benefits carefully in diabetic patients or dogs with a history of pancreatitis, and may recommend closer monitoring rather than outright avoidance. As with any prescription drug, a full medical history — including current medications — should be reviewed before starting treatment to check for interactions.

Can this be given long-term for a chronic condition like kidney disease?

Capromorelin's FDA approval covers general appetite stimulation and does not restrict use to a specific number of days, and many dogs with chronic diseases such as chronic kidney disease take it for weeks to months under veterinary supervision. The International Renal Interest Society (IRIS) staging guidelines for chronic kidney disease emphasize that preserving adequate caloric and protein intake is central to slowing disease progression and maintaining quality of life, which is where a long-term appetite stimulant can fit into the broader management plan (International Renal Interest Society, 2023).

Dogs on extended courses are usually rechecked periodically with bloodwork and weight checks to confirm the drug is still needed and that no new tolerance or side effects have developed. Long-term use works best paired with a specific therapeutic diet and treatment of the primary disease rather than as a standalone fix for chronic poor appetite.

Does the cat version (Elura) work the same way, and is it interchangeable with Entyce?

Elura, the feline formulation of capromorelin, was approved by the FDA in 2021 specifically for appetite stimulation in cats and uses a different concentration and flavoring designed for feline dosing and palatability (U.S. Food and Drug Administration, 2021). Entyce and Elura are not interchangeable milliliter-for-milliliter because the drug concentrations differ between the two products, so cat owners should use only the feline-labeled formulation and dose prescribed by their veterinarian.

Cats are especially prone to a dangerous complication called hepatic lipidosis when they stop eating for more than a couple of days, which is one reason feline anorexia is treated more urgently than in dogs and why an FDA-approved feline-specific option was a meaningful addition for veterinarians managing sick cats (Cornell Feline Health Center, 2021).